National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

From the 11/19/2021 release of VAERS data:

Found 2 cases where Vaccine targets Influenza or Pneumonia or Shingles (FLU(H1N1) or FLU3 or FLU4 or FLUA3 or FLUA4 or FLUC3 or FLUC4 or FLUN(H1N1) or FLUN3 or FLUN4 or FLUR3 or FLUR4 or FLUX or FLUX(H1N1) or H5N1 or PNC or PNC10 or PNC13 or PPV or VARZOS) and Symptom is Arterial thrombosis or Arterial thrombosis limb or Axillary vein thrombosis or Blood fibrinogen increased or Complement factor C1 increased or Complement factor C3 increased or Complement factor C4 increased or Complement factor increased or Deep vein thrombosis or Platelet adhesiveness increased or Platelet dysfunction or Platelet function test abnormal or Pulmonary embolism or Secondary thrombocytosis or Thrombectomy or Thrombin-antithrombin III complex increased or Thrombin time abnormal or Thrombocytopenia or Thrombocytopenic purpura or Thrombolysis or Thrombophlebitis or Thrombosis or Thrombotic microangiopathy or Thrombotic stroke or Thrombotic thrombocytopenic purpura or Vena cava embolism or Vena cava thrombosis or Venous occlusion and Patient Died and Vaccination Date from '2018-01-01' to '2019-12-31'

Government Disclaimer on use of this data

Table

   
AgeVaccine/ManufacturerVaccine DoseYear of DeathCountPercent
UnknownVARZOS / GLAXOSMITHKLINE BIOLOGICALS12018150%
VARZOS / GLAXOSMITHKLINE BIOLOGICALS12019150%
VARZOS / GLAXOSMITHKLINE BIOLOGICALS1total2100%
VARZOS / GLAXOSMITHKLINE BIOLOGICALStotal2100%
total2100%
TOTAL2100%



Case Details

VAERS ID: 857290 (history)  
Form: Version 2.0  
Age:   
Sex: Female  
Location: California  
Vaccinated:2019-05-15
Onset:2019-05-01
Submitted: 0000-00-00
Entered: 2020-01-20
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER (SHINGRIX) / GLAXOSMITHKLINE BIOLOGICALS 4257F / 1 - / -

Administered by: Unknown       Purchased by: ?
Symptoms: Blister, Death, Deep vein thrombosis, Erythema, Eyelid margin crusting, Ophthalmic herpes zoster, Pneumonia
SMQs:, Severe cutaneous adverse reactions (broad), Anaphylactic reaction (broad), Embolic and thrombotic events, venous (narrow), Thrombophlebitis (broad), Eosinophilic pneumonia (broad), Periorbital and eyelid disorders (narrow), Ocular infections (narrow), Hypersensitivity (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Infective pneumonia (narrow), Opportunistic infections (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2019-12-15
   Days after onset: 228
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: ERYTHROMYCIN OINTMENT
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: USGLAXOSMITHKLINEUS202000

Write-up: DVT; Pneumonia; Pharmacist states the patient''s death; forehead redness; forehead; crusting of the eyes; Ocular shingles; This case was reported by a pharmacist via call center representative and described the occurrence of unknown cause of death in a 88-year-old female patient who received Herpes zoster (Shingrix) (batch number 4257F, expiry date unknown) for prophylaxis. Co-suspect products included erythromycin (Erythromycin Ointment) for prophylaxis. On 15th May 2019, the patient received the 1st dose of Shingrix. On an unknown date, the patient started Erythromycin Ointment at an unknown dose and frequency. In May 2019, less than a week after receiving Shingrix and an unknown time after starting Valacyclovir, the patient experienced ophthalmic herpes zoster (serious criteria GSK medically significant). On 22nd May 2019, the patient experienced erythema, blister and eye crusting. On 15th December 2019, the patient experienced unknown cause of death (serious criteria death and GSK medically significant). On an unknown date, the patient experienced dvt (serious criteria GSK medically significant) and pneumonia (serious criteria GSK medically significant). The patient was treated with valaciclovir hydrochloride (Valacyclovir) and artificial tears nos (Artificial Tears). Erythromycin Ointment was discontinued. On an unknown date, the outcome of the unknown cause of death was fatal and the outcome of the ophthalmic herpes zoster, dvt, pneumonia, erythema, blister and eye crusting were unknown. The patient died on 15th December 2019. The reported cause of death was unknown cause of death. The reporter considered the unknown cause of death to be unrelated to Shingrix. It was unknown if the reporter considered the ophthalmic herpes zoster, dvt, pneumonia, erythema, blister and eye crusting to be related to Shingrix. Additional details were provided as follows: The patient was received Shingrix developed ocular shingles within one week. The medical team were unsure if it was herpes, but the chart notes not clearly bacterial or viral. Patient was prescribed erythromycin ointment for prophylaxis, then on 22nd May 2019 started getting forehead redness and blisters, crusting of the eyes, and she stopped erythromycin.The treatment was changed to artificial tears and started Valcyclovir 1g, 1 BID for 10 days. Patient had consult with ophthalmology and was treated with artificial tears. The consult noted "no evidence of herpetic uvelitis, keratitis, or retinitis in right eye and a treatment with antiviral medication was continue. On 15th December 2019, the patient died exact cause of death unknown. The patient had multiple issues including DVT and pneumonia, and patient elected for comfort care instead of treatment. Pharmacist states the patient''s death does not appear to be related to Shingrix.; Reported Cause(s) of Death: Death


VAERS ID: 1261110 (history)  
Form: Version 2.0  
Age:   
Sex: Male  
Location: South Carolina  
Vaccinated:2018-05-22
Onset:2018-05-01
Submitted: 0000-00-00
Entered: 2021-04-27
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARZOS: ZOSTER (SHINGRIX) / GLAXOSMITHKLINE BIOLOGICALS - / 1 - / -

Administered by: Unknown       Purchased by: ?
Symptoms: Acute kidney injury, Anoxia, Autopsy, Blood creatinine increased, Blood sodium decreased, Blood urea increased, Bronchitis chronic, Cardiac arrest, Cardiogenic shock, Central venous catheterisation, Condition aggravated, Death, Endotracheal intubation, Feeding disorder, Fluid intake reduced, Glomerulonephritis membranous, Hyponatraemia, Hypotension, Hypovolaemia, Hypoxia, Influenza like illness, Malaise, Metabolic encephalopathy, Multiple organ dysfunction syndrome, Muscle contractions involuntary, Myalgia, Myocardial infarction, Pyrexia, Rash, Renal disorder, Renal tubular necrosis, Respiratory failure, Seizure, Shock, Tachycardia, Thrombocytopenia, Transaminases increased, Viral infection, Viral test negative
SMQs:, Torsade de pointes/QT prolongation (broad), Rhabdomyolysis/myopathy (broad), Acute renal failure (narrow), Cardiac failure (narrow), Liver related investigations, signs and symptoms (narrow), Anaphylactic reaction (narrow), Angioedema (broad), Asthma/bronchospasm (broad), Haematopoietic thrombocytopenia (narrow), Neuroleptic malignant syndrome (broad), Systemic lupus erythematosus (broad), Myocardial infarction (narrow), Anticholinergic syndrome (broad), Arrhythmia related investigations, signs and symptoms (broad), Retroperitoneal fibrosis (broad), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (narrow), Torsade de pointes, shock-associated conditions (broad), Hypovolaemic shock conditions (narrow), Toxic-septic shock conditions (narrow), Anaphylactic/anaphylactoid shock conditions (narrow), Hypoglycaemic and neurogenic shock conditions (narrow), Convulsions (narrow), Embolic and thrombotic events, arterial (narrow), Embolic and thrombotic events, venous (narrow), Dystonia (broad), Acute central respiratory depression (narrow), Pulmonary hypertension (broad), Guillain-Barre syndrome (broad), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (narrow), Noninfectious meningitis (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (broad), Hyponatraemia/SIADH (narrow), Cardiomyopathy (broad), Eosinophilic pneumonia (broad), Renovascular disorders (broad), Hypotonic-hyporesponsive episode (broad), Generalised convulsive seizures following immunisation (narrow), Chronic kidney disease (broad), Hypersensitivity (narrow), Tumour lysis syndrome (broad), Tubulointerstitial diseases (broad), Respiratory failure (narrow), Tendinopathies and ligament disorders (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (narrow), Hypoglycaemia (broad), Infective pneumonia (broad), Dehydration (narrow), Hypokalaemia (broad), Sepsis (broad), Immune-mediated/autoimmune disorders (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2018-05-30
   Days after onset: 29
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: RITUXIMAB
Current Illness: Glomerulonephritis membranous (diagnosed with membranous glomerulonephritis); Renal disorder (had long standing kidney problems)
Preexisting Conditions: Medical History/Concurrent Conditions: Biopsy (had a biopsy on February 2018.)
Allergies:
Diagnostic Lab Data: Test Date: 20180526; Test Name: Creatinine increased; Result Unstructured Data: (Test Result:value not reported,Unit:unknown,Normal Low:,Normal High:); Test Date: 20180526; Test Name: Hyponatremia; Result Unstructured Data: (Test Result:value not reported,Unit:unknown,Normal Low:,Normal High:); Test Date: 20180526; Test Name: Blood urea nitrogen increased; Result Unstructured Data: (Test Result:value not reported,Unit:unknown,Normal Low:,Normal High:); Test Date: 20180526; Test Name: body temperature; Result Unstructured Data: (Test Result:103.9,Unit:degree F,Normal Low:,Normal High:); Test Date: 201805; Test Name: lab test; Test Result: Negative ; Test Date: 20180526; Test Name: Transaminitis; Result Unstructured Data: (Test Result:value not reported,Unit:unknown,Normal Low:,Normal High:)
CDC Split Type: USGLAXOSMITHKLINEUS202109

Write-up: suffered spontaneous contractions / had a central line placed; tachycardic / (intubation removed after) and hypotensive; hypoxemia; Chronic bronquitis; never recovered pulmonary activity and died / Respiratory failure with hypoxemia; Elevated MI and shock; Elevated MI and shock; kidney problem / Diagnosed with membranous glomerulonephritis / worsened /hospitalized after getting worse; kidney problem / Diagnosed with membranous glomerulonephritis / worsened /hospitalized after getting worse; extremely ill kidneys shut down / developed acute renal failure; tubular necrosis; Metabolic encephalopathy (due to hyponatremia and anoxia); anoxia; Thrombocytopenia; hypotension (secondary to hypovolemia). /hypotensive; secondary to hypovolemia; Rash on the lower extremities; Decreased fluid and nourishment intake due to inability to eat and drink; Decreased fluid / due to inability to eat and drink; Hyponatremia; Transaminitis; Increased /creatinine; Increased BUN and creatinine; malaise; flu like symptoms / flu like illness; viral-like symptoms; myalgia; fever / Fever 103.9?F; multiorgan failure; rapidly decompensated with seizure; This case was reported by a physician via call center representative and described the occurrence of respiratory failure in a 62-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. The patient''s past medical history included biopsy (had a biopsy on February 2018.). Previously administered products included prednisone, ciclosporin, immunosuppressive therapy (had exacerbation of the problem and was treated with immunosuppressive therapy using rituximab twice) and rituximab. Concurrent medical conditions included renal disorder (had long standing kidney problems) and glomerulonephritis membranous (diagnosed with membranous glomerulonephritis). Concomitant products included rituximab. On 22nd May 2018, the patient received the 1st dose of Shingrix. In May 2018, less than 2 weeks after receiving Shingrix, the patient experienced seizure (serious criteria hospitalization and GSK medically significant) and multi-organ failure (serious criteria hospitalization and GSK medically significant). On 22nd May 2018, the patient experienced influenza like illness (serious criteria hospitalization), viral infection (serious criteria hospitalization), myalgia (serious criteria hospitalization), fever (serious criteria hospitalization) and malaise (serious criteria hospitalization). On 26th May 2018, the patient experienced thrombocytopenia (serious criteria hospitalization and GSK medically significant), hypotension (serious criteria hospitalization), hypovolemia (serious criteria hospitalization), rash (serious criteria hospitalization), unable to eat (serious criteria hospitalization), fluid intake reduced (serious criteria hospitalization), hyponatremia (serious criteria hospitalization), transaminitis (serious criteria hospitalization), creatinine increased (serious criteria hospitalization) and blood urea nitrogen increased (serious criteria hospitalization). On 29th May 2018, the patient experienced respiratory failure (serious criteria death, hospitalization and GSK medically significant), myocardial infarction (serious criteria hospitalization and GSK medically significant), cardiogenic shock (serious criteria hospitalization and GSK medically significant), glomerulonephritis membranous (serious criteria hospitalization and GSK medically significant), condition aggravated (serious criteria hospitalization), acute renal failure (serious criteria hospitalization and GSK medically significant), tubular necrosis (serious criteria hospitalization and GSK medically significant), metabolic encephalopathy (serious criteria hospitalization and GSK medically significant), anoxia (serious criteria hospitalization and GSK medically significant), hypoxemia (serious criteria hospitalization and GSK medically significant) and chronic bronchitis (serious criteria hospitalization). On 30th May 2018, the patient experienced tachycardia (serious criteria hospitalization) and muscle contractions involuntary (serious criteria hospitalization). On 30th May 2018, the outcome of the respiratory failure was fatal. On an unknown date, the outcome of the myocardial infarction, cardiogenic shock, glomerulonephritis membranous, condition aggravated, acute renal failure, thrombocytopenia, tubular necrosis, metabolic encephalopathy, anoxia, seizure, hypoxemia, multi-organ failure, chronic bronchitis, hypotension, tachycardia, hypovolemia, muscle contractions involuntary, influenza like illness, viral infection, myalgia, fever, rash, malaise, unable to eat, fluid intake reduced, hyponatremia, transaminitis, creatinine increased and blood urea nitrogen increased were unknown. The patient died on 30th May 2018. The reported cause of death was respiratory failure. An autopsy was performed. It was unknown if the reporter considered the respiratory failure, myocardial infarction, cardiogenic shock, glomerulonephritis membranous, condition aggravated, acute renal failure, thrombocytopenia, tubular necrosis, metabolic encephalopathy, anoxia, seizure, hypoxemia, multi-organ failure, chronic bronchitis, hypotension, tachycardia, hypovolemia, muscle contractions involuntary, influenza like illness, viral infection, myalgia, fever, rash, malaise, unable to eat, fluid intake reduced, hyponatremia, transaminitis, creatinine increased and blood urea nitrogen increased to be related to Shingrix. Additional details were provided as follows: The age at vaccination was not reported. The patient had long standing kidney problems and was various drugs for the past 20 years. The patient had last Rituximab treatment on 16th May 2018. As per MD (Doctor of Medicine) insistence patient got Shingrix vaccine. The patient experienced flu like symptoms, myalgia, fever and malaise and his condition worsened. On 26th May 2018, the patient was hospitalized after getting worse. The patient got extremely ill, kidneys shut down, there was hypotension (secondary to hypovolemia), decreased fluid and nourishment intake due to inability to eat and drink, fever 103.9 degree Fahrenheit, rash on the lower extremities, thrombocytopenia, hyponatremia decreased sodium, blood urea nitrogen increased and creatinine increased and transaminitis. Initial hospital could not do dialysis due to lack of equipment and was transferred to reporters hospital with a diagnose of membranous glomerulonephritis. On 29th May 2018, the patient was transferred to reporter''s hospital and patient died in less than 24 hours. The patient developed acute renal failure with tubular necrosis, respiratory failure with hypoxemia, chronic bronchitis (found in reporter''s hospital), metabolic encephalopathy (due to hyponatremia and anoxia), elevated MI (myocardial infarction) and shock. The patient had viral-like symptoms, tests for several common viruses came negative. As per physician notes patient rapidly decompensated with seizure and multiorgan failure, questionable meningitis versus immune response; pathologist (reporter) confirms patient did not have meningitis. On 30th May 2018, the patient was declared DNR (do-not-resuscitate) by family and later became asystolic, suffered spontaneous contractions and had a central line placed. The patient became tachycardic and hypotensive and was removed from intubation and 2 minutes later never recovered pulmonary activity and died. The health care professional was performing autopsy on a patient. No vaccine administration information available to reporter. The reporter consented to follow-up. This case had been linked with US2021090816, reported by the same reporter.; Sender''s Comments: US-GLAXOSMITHKLINE-US2021090816:same reporter (wife?s case); Reported Cause(s) of Death: Respiratory failure


New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?TABLE=ON&GROUP1=AGE&GROUP2=VMAN&GROUP3=VDO&GROUP4=DEAY&EVENTS=ON&SYMPTOMS[]=Arterial+thrombosis+%2810003178%29&SYMPTOMS[]=Arterial+thrombosis+limb+%2810003180%29&SYMPTOMS[]=Axillary+vein+thrombosis+%2810003880%29&SYMPTOMS[]=Blood+fibrinogen+increased+%2810005521%29&SYMPTOMS[]=Complement+factor+C1+increased+%2810051554%29&SYMPTOMS[]=Complement+factor+C3+increased+%2810010126%29&SYMPTOMS[]=Complement+factor+C4+increased+%2810050982%29&SYMPTOMS[]=Complement+factor+increased+%2810061049%29&SYMPTOMS[]=Deep+vein+thrombosis+%2810051055%29&SYMPTOMS[]=Platelet+adhesiveness+increased+%2810035515%29&SYMPTOMS[]=Platelet+dysfunction+%2810073391%29&SYMPTOMS[]=Platelet+function+test+abnormal+%2810061539%29&SYMPTOMS[]=Pulmonary+embolism+%2810037377%29&SYMPTOMS[]=Secondary+thrombocytosis+%2810083158%29&SYMPTOMS[]=Thrombectomy+%2810043530%29&SYMPTOMS[]=Thrombin-antithrombin+III+complex+increased+%2810053968%29&SYMPTOMS[]=Thrombin+time+abnormal+%2810051319%29&SYMPTOMS[]=Thrombocytopenia+%2810043554%29&SYMPTOMS[]=Thrombocytopenic+purpura+%2810043561%29&SYMPTOMS[]=Thrombolysis+%2810043568%29&SYMPTOMS[]=Thrombophlebitis+%2810043570%29&SYMPTOMS[]=Thrombosis+%2810043607%29&SYMPTOMS[]=Thrombotic+microangiopathy+%2810043645%29&SYMPTOMS[]=Thrombotic+stroke+%2810043647%29&SYMPTOMS[]=Thrombotic+thrombocytopenic+purpura+%2810043648%29&SYMPTOMS[]=Vena+cava+embolism+%2810047193%29&SYMPTOMS[]=Vena+cava+thrombosis+%2810047195%29&SYMPTOMS[]=Venous+occlusion+%2810058990%29&VAX[]=FLU(H1N1)&VAX[]=FLU3&VAX[]=FLU4&VAX[]=FLUA3&VAX[]=FLUA4&VAX[]=FLUC3&VAX[]=FLUC4&VAX[]=FLUN(H1N1)&VAX[]=FLUN3&VAX[]=FLUN4&VAX[]=FLUR3&VAX[]=FLUR4&VAX[]=FLUX&VAX[]=FLUX(H1N1)&VAX[]=H5N1&VAX[]=PNC&VAX[]=PNC10&VAX[]=PNC13&VAX[]=PPV&VAX[]=VARZOS&VAXTYPES[]=Influenza&VAXTYPES[]=Pneumonia&VAXTYPES[]=Shingles&DIED=Yes&VAX_YEAR_LOW=2018&VAX_YEAR_HIGH=2019


Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166